

Yitshak Francis

Scientific advisor and board observer

Company: **Qrons**

Founded in 2016, Qrons is a publicly traded, preclinical biotechnology company, developing advanced cell-based solutions to combat neurological injuries. While we are laser-focused on traumatic brain injury (TBI), our technology could potentially treat a wide range of neurodegenerative diseases.

Our TBI treatment integrates proprietary, engineered mesenchymal stem cells (MSCs), 3D printable scaffolding, smart materials and a novel delivery system.

We believe this combination will reduce neuronal loss and functional impairment and possibly regenerate brain tissue and function for TBI patients.

Daria Lemann-Blumenthal

CEO

Company: **Belkin Laser**

BELKIN Laser is developing an automated one-second glaucoma laser treatment, aimed at revolutionizing accessibility to glaucoma care by becoming the first-line choice for glaucoma therapy for every patient, all over the world. | Glaucoma is a chronic, asymptomatic disease, causing progressive optic nerve degeneration. It is the leading cause of irreversible blindness globally. Although the disease is incurable, progression may be delayed by reducing IOP (Intraocular Pressure), thus preventing visual field impairment and blindness. | BELKIN Laser's innovative technology provides a solution not only for Open Angle Glaucoma (70% of total glaucoma cases) but is also an exclusive solution for Angle Closure Glaucoma (ACG) (30%), which is most common among Asian populations.

Nadav Peles

Co-founder / Acting CEO

Company: **Ta Geza**

TaGeza is a privately held preclinical company dedicated to the study of cancer stem cells in the most malignant and deadliest forms of cancer. TaGeza seeks to identify central markers of highly aggressive cancer stem cells and develop drugs to target this cell population with the goal of eradicating different forms of treatment-resistant cancers as a combination therapy with standard treatments. By using high passage in-vivo expansion of tumor implants, TaGeza's platform enriches the cancer stem cell population, and provides a unique method for the discovery of novel therapeutic targets. Using its cutting-edge technology, as well as its method of in-vivo and in-vitro validation, the company is currently evaluating proprietary target candidates for the development of conjugated antibodies. TaGeza strives to partner with pharma and biotech companies to develop certain targets, and at the same time to build stand-alone capabilities for the development of additional targets.

Tomer Behor

CEO

Company: **RenewSenses**

RenewSenses conveys vision through sound for people who are blind or visually impaired, enabling them a new form of independence. Our IP-protected "sensory language" combines computer vision and create a new sensory experience for users, also shown to activate areas in the visual cortex of people who are blind from birth by the lab of Prof. Amir Amedi (co-founder). While focusing at first on our wearable sensory substitution device, the "EyeMusic", we aim to use this method to offer various solutions for eyes-free access to the invisible - for numerous aspects of the life of people with visual impairment, and for other forms of human sensory enhancements.

Seth Salpeter

Co-founder & CTO

Company: **Curesponse**

Curesponse is an innovative cancer diagnostic company developing the next generation of personalized medicine. The company has established a 3-dimensional platform for modeling cancer dynamics and drug response. The system preserves the cancer tissue microenvironment accurately reflecting the cancer growth found in the body and can be harnessed to create a personalized cancer diagnostic to determine drug response.

Patients and clinicians can send samples of their tumor to be tested with a panel of anti-cancer therapies predetermined by genomic screening and physician assessment. The patient will then be informed which drug is the preferred therapy for their tumor, optimizing treatment and increasing their chances of survival. Moreover, the test can be used by pharmaceutical companies to expedite their drug development process as well as for clinical trials as a patient inclusion criteria.

Yoram Eshel

CEO

Company: **On-Sight**

On-Sight has developed a revolutionary algorithm for ultrasound imaging that eliminates the need for an expert.

Based on deep learning and geometric processing a unique algorithm for guided ultrasound imaging acquisition was developed as well as the capability for automatic ultrasound imaging analysis.

The software works both with On-Sight's proprietary device and standard equipment, enabling any ultrasound imaging device to become an automatic image analysis system.

The system has a wide-range of applications including the emergency room, ambulance, family physician office, OB/GYN clinic, dermatology clinic, and even eventually at home. The systems simplicity and ease-of-use will even allow non-experts to be able to capture ultrasound images, while the system automatically analyzes and processes the data.

Fuad Fares

Co-founder

Company: **CanCuRX Ltd.**

Striding towards a novel treatment for one of the deadliest cancers.

Based on mushroom-derived compound, inhibiting progression of pancreatic cancer cells.

University of Haifa researchers working to improve survival for patients with pancreatic cancer joined with Carmel, the University's economic corporation, and established CanCurX to further develop a novel treatment for this deadly disease.

Leading research and development is Prof. Fuad Fares of the Faculty of Natural Sciences. In 2009 he founded biomedical start-up Prolor Biotech, which engineered a platform that prolongs the lifespan and efficacy of therapeutic proteins in treating deficiencies. (Prolor Biotech was acquired by Opko Health in 2013.)

Prof. Fares and Dr. Lital Sharvit have accomplished successful research leading toward the development of a novel treatment for pancreatic cancer. Their discovery is based on properties of a mushroom-derived compound that arrest pancreatic cell growth.

Noam Shomron

CSO

Company: **Variantx**

Variantx is a clinically accredited diagnostic lab and OEM vendor providing genomic diagnostic solutions that bridge the gap between scientific advancements and their implementation in the clinic. Our Genomic Intelligence® platform, combined with our clinical accreditation and the economy of a “labless” lab (achieved by outsourcing commoditized sequencing to low cost providers), enables us to uniquely deliver market changing, high complexity clinical genomic tests and OEM solutions in radically different ways.

Our disruptive and innovative technology utilizes whole genome sequencing (WGS). In a single sequenced DNA sample our algorithms identify and annotate small sequence changes, structural variants, tandem repeats and mitochondrial variants. Offered as our Variantx Unity™ test to clinicians, the all-in-one genomic test for rare inherited disorders delivers high diagnostic yield, fast turnaround and significant cost savings.

Our OEM solutions enable hospitals and labs, with minimal investment, to generate significant, high-margin revenue by insourcing tests that are currently referred to external labs. Customers are able to quickly launch new genomic tests with minimal R&D and certification effort using our full solution stack which includes assay design, validation, medicolegal framework and automation integration.

Ayala Pollack

Inventor and medical director

Company: **OphtimedRx**

OphtimedRx develops leading products for treatment of ophthalmic diseases which result in blindness and with unmet medical needs. Two major diseases are in the focus of OphtimedRx, proliferative vitreo-retinopathy (PVR) and dry age-related macular degeneration (AMD), in particular geographic atrophy. The company was established in Israel in 2015 by Prof. Ayala Pollack, M.D, former Head of the Ophthalmology Department, Kaplan Medical Center.

Hila Goldman Aslan

CEO

Company: **DiA Imaging Analysis**

DiA Imaging Analysis is a B2B Israeli-based startup company in the field of Ultrasound analysis.

DiA invented a cognitive image processing technology based on advance pattern recognition and machine learning algorithms.

We create fully automated tools to evaluate ultrasound images with FDA/CE cleared products for "Cardiac Ultrasound" evaluation and now expanding to additional areas beyond Cardiology.

Our Offering: Accurate, Quick, Reproducible – Automated Imaging Analysis.

Jessica Weiss

CEO

Company: **Lydus Medical**

VISION

To enable surgeons to automate their techniques by providing them plug and play tools for easier and faster procedures and consistent outcomes.

THE NEED

Anastomosis is surgical coupling of separate tubular organs.

Anastomosis of small organs such as blood vessels, bile duct and nerves, are the most technically challenging and time consuming step in reconstructive surgery, hand surgery, coronary artery bypass, AV fistula and organ transplantation.

The gold standard for micro organ anastomosis creation is manual sewing which requires special expertise, it's learning curve is very slow and long, Clinical risks such as thrombosis and leaks may be involved and it's success depends solely on the surgeon's performance. The procedures are done under expensive magnifying microscope which are not always available in the operating rooms.

SOLUTION

Lydus Medical develops the Vessel Trap - A System which delivers proprietary needles and sutures to optimal positions